• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

2013年至2017年德国一家三级转诊中心中重度神经营养性角膜病变的发病率、患病率及转归

Incidence, prevalence, and outcome of moderate to severe neurotrophic keratopathy in a German tertiary referral center from 2013 to 2017.

作者信息

Roth Mathias, Dierse Sebastian, Alder Jan, Holtmann Christoph, Geerling Gerd

机构信息

Department of Ophthalmology, Heinrich-Heine University Duesseldorf, Moorenstr. 5, 40225, Duesseldorf, Germany.

出版信息

Graefes Arch Clin Exp Ophthalmol. 2022 Jun;260(6):1961-1973. doi: 10.1007/s00417-021-05535-z. Epub 2022 Jan 6.

DOI:10.1007/s00417-021-05535-z
PMID:34989864
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9061695/
Abstract

BACKGROUND

Neurotrophic keratopathy (NK) is an orphan disease, with an estimated prevalence of 1-5/10,000. No data regarding the incidence exists. The primary aim was to evaluate incidence and prevalence of NK at a tertiary referral center in Germany, and the secondary aim was to analyze demographic parameters, etiology, and clinical features and therapeutic outcomes.

METHODS AND MATERIAL

All patients treated for NK with serum eye drops (SED), amnionic membrane transplantation (AMT), or penetrating keratoplasty (PK) in 2013-2017 were identified. Age, sex, etiology of NK, visual acuity, disease stage, treatment, and visual acuity were analyzed. Incidence and prevalence of NK in our hospital and the overall population of the city were calculated.

RESULTS

In 63 eyes of 60 patients (56.7% male; 68 ± 16 years), the most common underlying diseases were herpetic infections (23.8%), neurological causes (19%), and diabetes mellitus (14.3%). The annual incidence of NK in our tertiary referral center ranges between 5/10,000 and 3/10,000, the prevalence between 9/10,00 and 22/10,000. In all patients treated with corneal ulcers, the prevalence was up to 27% (2706/10,000). The incidence in the overall population is estimated at 0.1-0.3/10,000, the prevalence at 0.2-0.5/10,000 to 0.5/10,000.

CONCLUSION

Based on our assessment, the prevalence of NK in the overall population is lower than estimated before. However, in patients with corneal ulcers, the percentage of NK is comparably high. The disease may still be underdiagnosed due to the variety of underlying disorders and unknown comorbidities. Thus, in cases of therapy-refractive superficial keratopathy or ulcerations, NK should be considered more frequently.

摘要

背景

神经营养性角膜病变(NK)是一种罕见病,估计患病率为1-5/10000。目前尚无关于发病率的数据。主要目的是评估德国一家三级转诊中心NK的发病率和患病率,次要目的是分析人口统计学参数、病因、临床特征及治疗效果。

方法与材料

确定2013年至2017年期间所有接受血清眼药水(SED)、羊膜移植(AMT)或穿透性角膜移植术(PK)治疗NK的患者。分析患者的年龄、性别、NK病因、视力、疾病阶段、治疗方法及视力情况。计算我院及该市总人口中NK的发病率和患病率。

结果

60例患者的63只眼(男性占56.7%;年龄68±16岁),最常见的基础疾病为疱疹感染(23.8%)、神经病因(19%)和糖尿病(14.3%)。我院三级转诊中心NK的年发病率在5/10000至3/10000之间,患病率在9/10000至22/10000之间。在所有接受角膜溃疡治疗的患者中,患病率高达27%(2706/10000)。总体人群中的发病率估计为0.1-0.3/10000,患病率为0.2-0.5/10000至0.5/10000。

结论

根据我们的评估,总体人群中NK的患病率低于之前的估计。然而,在角膜溃疡患者中,NK的比例相对较高。由于潜在疾病种类繁多且合并症不明,该病可能仍未得到充分诊断。因此,在治疗屈光性浅层角膜病变或溃疡时,应更频繁地考虑NK。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a150/9061695/6c8ba5588cce/417_2021_5535_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a150/9061695/79435ee92758/417_2021_5535_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a150/9061695/84bbe0337c1f/417_2021_5535_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a150/9061695/56b41a3d1973/417_2021_5535_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a150/9061695/a2ac9fc8a7ce/417_2021_5535_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a150/9061695/6c8ba5588cce/417_2021_5535_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a150/9061695/79435ee92758/417_2021_5535_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a150/9061695/84bbe0337c1f/417_2021_5535_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a150/9061695/56b41a3d1973/417_2021_5535_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a150/9061695/a2ac9fc8a7ce/417_2021_5535_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a150/9061695/6c8ba5588cce/417_2021_5535_Fig5_HTML.jpg

相似文献

1
Incidence, prevalence, and outcome of moderate to severe neurotrophic keratopathy in a German tertiary referral center from 2013 to 2017.2013年至2017年德国一家三级转诊中心中重度神经营养性角膜病变的发病率、患病率及转归
Graefes Arch Clin Exp Ophthalmol. 2022 Jun;260(6):1961-1973. doi: 10.1007/s00417-021-05535-z. Epub 2022 Jan 6.
2
Neurotrophic Keratopathy in the United States: An Intelligent Research in Sight Registry Analysis.美国的神经营养性角膜病变:智能研究在眼前的分析。
Ophthalmology. 2022 Nov;129(11):1255-1262. doi: 10.1016/j.ophtha.2022.06.019. Epub 2022 Jun 26.
3
Neurotrophic keratopathy: An updated understanding.神经营养性角膜病变:最新认识
Ocul Surf. 2023 Oct;30:129-138. doi: 10.1016/j.jtos.2023.09.001. Epub 2023 Sep 4.
4
Assessment of response to multimodal management of neurotrophic corneal disease.评估神经营养性角膜疾病的多模态管理反应。
Ocul Surf. 2021 Jan;19:330-335. doi: 10.1016/j.jtos.2020.11.003. Epub 2020 Nov 12.
5
Prevalence and clinical characteristics of neurotrophic keratopathy in hispanic population in northeastern Mexico.墨西哥东北部西班牙裔人群中神经营养性角膜病变的患病率及临床特征。
Int Ophthalmol. 2023 Sep;43(9):3257-3262. doi: 10.1007/s10792-023-02726-x. Epub 2023 May 4.
6
Long-term restoration of corneal sensitivity in neurotrophic keratopathy after rhNGF treatment.神经营养性角膜病变经 rhNGF 治疗后角膜感觉的长期恢复。
Eur J Ophthalmol. 2022 Jan;32(1):NP15-NP18. doi: 10.1177/1120672120953343. Epub 2020 Aug 27.
7
Neurotrophic keratopathy: current challenges and future prospects.神经营养性角膜病变:当前的挑战与未来展望。
Ann Med. 2022 Dec;54(1):666-673. doi: 10.1080/07853890.2022.2045035.
8
Neurotrophic Keratopathy in Pediatric Patients.小儿患者的神经营养性角膜病变
Semin Ophthalmol. 2021 May 19;36(4):289-295. doi: 10.1080/08820538.2021.1896747. Epub 2021 Mar 23.
9
Corneal neurotization in the management of neurotrophic keratopathy: A review of the literature.角膜神经化在神经营养性角膜病变治疗中的应用:文献综述
J Fr Ophtalmol. 2023 Jan;46(1):83-96. doi: 10.1016/j.jfo.2022.09.007. Epub 2022 Dec 5.
10
[Pathogenesis and epidemiology of neurotrophic keratopathy].[神经营养性角膜病变的发病机制与流行病学]
Ophthalmologe. 2019 Feb;116(2):109-119. doi: 10.1007/s00347-018-0823-9.

引用本文的文献

1
[Neurotrophic keratopathy and corneal ulcers in diabetes mellitus].[糖尿病中的神经营养性角膜病变与角膜溃疡]
Ophthalmologie. 2025 May;122(5):378-382. doi: 10.1007/s00347-025-02198-7. Epub 2025 Mar 5.
2
Herpes simplex keratitis: A brief clinical overview.单纯疱疹性角膜炎:简要临床概述。
World J Virol. 2024 Mar 25;13(1):89934. doi: 10.5501/wjv.v13.i1.89934.
3
Phase IV Multicenter, Prospective, Open-Label Clinical Trial of Cenegermin (rhNGF) for Stage 1 Neurotrophic Keratopathy (DEFENDO).用于1期神经营养性角膜病变的西奈吉明(重组人神经生长因子)的IV期多中心、前瞻性、开放标签临床试验(DEFENDO)

本文引用的文献

1
Development of the neurotrophic keratopathy questionnaire: qualitative research.神经营养性角膜病变问卷的开发:定性研究
J Patient Rep Outcomes. 2020 May 4;4(1):30. doi: 10.1186/s41687-020-00192-y.
2
Risk of Corneal Ulcer in Patients with Diabetes Mellitus: A Retrospective Large-Scale Cohort Study.糖尿病患者角膜溃疡的风险:一项回顾性大规模队列研究。
Sci Rep. 2020 Apr 30;10(1):7388. doi: 10.1038/s41598-020-64489-0.
3
Neurotrophic keratitis: Frequency, etiologies, clinical management and outcomes.神经营养性角膜炎:频率、病因、临床管理和结局。
Ophthalmol Ther. 2024 Feb;13(2):553-570. doi: 10.1007/s40123-023-00866-y. Epub 2024 Jan 4.
4
Corneal perforation after corneal foreign body - Case Report.角膜异物后角膜穿孔-病例报告。
Rom J Ophthalmol. 2023 Jan-Mar;67(1):77-80. doi: 10.22336/rjo.2023.14.
5
Neurotrophic Keratopathy Treated with Topical Recombinant Human Nerve Growth Factor (Cenegermin): Case Series Study with Long-Term Follow-Up.局部应用重组人神经生长因子(西奈吉明)治疗神经营养性角膜病变:长期随访的病例系列研究
Case Rep Ophthalmol. 2022 Aug 31;13(2):663-670. doi: 10.1159/000525923. eCollection 2022 May-Aug.
6
Topical human recombinant nerve growth factor for stage 1 Neurotrophic Keratitis: Retrospective case series of cenegermin treatment.外用人重组神经生长因子治疗1期神经营养性角膜炎:cenegermin治疗的回顾性病例系列
Am J Ophthalmol Case Rep. 2022 Jul 2;27:101649. doi: 10.1016/j.ajoc.2022.101649. eCollection 2022 Sep.
Ocul Surf. 2020 Apr;18(2):231-236. doi: 10.1016/j.jtos.2019.11.008. Epub 2019 Nov 20.
4
[Corneal neurotization].[角膜神经化]
Ophthalmologe. 2020 Mar;117(3):248-252. doi: 10.1007/s00347-019-00980-y.
5
Topical Recombinant Human Nerve Growth Factor (Cenegermin) for Neurotrophic Keratopathy: A Multicenter Randomized Vehicle-Controlled Pivotal Trial.标题:神经营养性角膜病变的局部重组人神经生长因子(Cenegermin):一项多中心随机对照关键性试验。
Ophthalmology. 2020 Jan;127(1):14-26. doi: 10.1016/j.ophtha.2019.08.020. Epub 2019 Aug 26.
6
Neurotrophic keratopathy: Pros and cons of current treatments.神经营养性角膜病变:当前治疗方法的利弊。
Ocul Surf. 2019 Oct;17(4):619-623. doi: 10.1016/j.jtos.2019.09.002. Epub 2019 Sep 14.
7
[Neurotrophic keratopathy : Principles, diagnostics and treatment].[神经营养性角膜病变:原理、诊断与治疗]
Ophthalmologe. 2019 Aug;116(8):797-810. doi: 10.1007/s00347-019-0946-7.
8
[Current and experimental treatment approaches for neurotrophic keratopathy].[神经营养性角膜病变的当前及实验性治疗方法]
Ophthalmologe. 2019 Feb;116(2):127-137. doi: 10.1007/s00347-018-0843-5.
9
Neurotrophic keratopathy.神经营养性角膜病变。
Prog Retin Eye Res. 2018 Sep;66:107-131. doi: 10.1016/j.preteyeres.2018.04.003. Epub 2018 Apr 23.
10
Phase I Trial of Recombinant Human Nerve Growth Factor for Neurotrophic Keratitis.重组人神经生长因子治疗神经营养性角膜炎的I期试验
Ophthalmology. 2018 Sep;125(9):1468-1471. doi: 10.1016/j.ophtha.2018.03.004. Epub 2018 Apr 10.